Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMN107 (Nilotinib) in Imatinib-Resistant/Intolerant CML
NCT00264160Phase 3Completed
- Sponsor
- Novartis
- Start
- May 2006
- Primary completion
- Nov 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of nilotinib in chronic myeloid leukemia (CML), sponsored by Novartis. Started May 2006; status: completed.
02
Drugs
nilotinib
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT00264160.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00264160.